Geekwire Health Tech

GeekWire editor Todd Bishop: On a cold, clear weekday morning last month, my quest to figure out whether I had COVID-19 in the early days of the pandemic took me to my back porch, where a mobile phlebotomist drew my blood. It had been 10 months since I was sick, and I had already received a negative result on a standard antibody test.  That earlier test was designed to detect the presence of the antibodies produced by the body’s immune system to ward off the virus that causes COVID-19. The negative result meant I probably didn't have COVID back in March. But given the possibility of a false negative in the antibody test, I wasn’t giving up that easily. And this test was different. This was a first-of-its kind diagnostic tool from Seattle-based Adaptive Biotechnologies, a company that develops technology to sequence the human immune system for the diagnosis and treatment of disease. T-cells are specialized cells that determine the human immune system’s response to disease. Adaptive says tell-tale signs of T